Aquestive Therapeutics (AQST) Receivables (2017 - 2026)

Aquestive Therapeutics' Receivables history runs 10 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• On a quarterly basis, Receivables fell 33.06% year-over-year to $8.5 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 33.06% decrease from a year earlier, with the FY2025 full-year figure at $27.5 million, up 180.26% from the prior year.
• Receivables slipped to $8.5 million in Q1 2026 per AQST's latest filing, from $27.5 million in the prior quarter.
• Across five years, Receivables topped out at $27.5 million in Q4 2025 and bottomed at $6.8 million in Q4 2022.
• The 5-year median for Receivables is $11.7 million (2024), against an average of $13.1 million.
• Across the five-year window, Receivables sank 55.0% in 2022 and jumped 180.26% in 2025, its largest moves.
• Year by year, Receivables stood at $6.8 million in 2022, then rose by 24.0% to $8.5 million in 2023, then climbed by 15.7% to $9.8 million in 2024, then soared by 180.26% to $27.5 million in 2025, then sank by 69.21% to $8.5 million in 2026.
• Per Business Quant, the three latest AQST Receivables figures stand at $8.5 million (Q1 2026), $27.5 million (Q4 2025), and $14.1 million (Q3 2025).